Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation

G. Mowatt; R. Hernández; M. Castillo; N. Lois; A. Elders; C. Fraser; O. Aremu; W. Amoaku; J. Burr; A. Lotery; C. Ramsay; A. Azuara-Blanco

doi:10.3310/hta18690

Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation

G. Mowatt, R. Hernández, M. Castillo, N. Lois, A. Elders, C. Fraser, O. Aremu, W. Amoaku, J. Burr, A. Lotery, C. Ramsay, A. Azuara-Blanco

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Results: In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity [95% confidence interval (CI)] was 88% (46% to 98%) and 78% (64% to 88%) respectively. For monitoring, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. The FFA for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (£39,769; QALYs 10.473) and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (£44,649; QALYs 10.575; incremental cost-effectiveness ratio £47,768). The least costly strategy had a 46.4% probability of being cost-effective at £30,000 willingness-to-pay threshold.

Original language	English
Pages (from-to)	1-253
Number of pages	253
Journal	Health Technology Assessment
Volume	18
Issue number	69
DOIs	https://doi.org/10.3310/hta18690
Publication status	Published - Nov 2014

Access to Document

10.3310/hta18690

Burr_2014_HTA_Optical
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Mowatt et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.
Final published version, 2.37 MB

Cite this

Mowatt, G., Hernández, R., Castillo, M., Lois, N., Elders, A., Fraser, C., Aremu, O., Amoaku, W., Burr, J., Lotery, A., Ramsay, C., & Azuara-Blanco, A. (2014). Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation. Health Technology Assessment, 18(69), 1-253. https://doi.org/10.3310/hta18690

@article{0aae57217d974c8995b514d05e9e69c2,

title = "Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation",

abstract = "Results: In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity [95% confidence interval (CI)] was 88% (46% to 98%) and 78% (64% to 88%) respectively. For monitoring, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. The FFA for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (£39,769; QALYs 10.473) and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (£44,649; QALYs 10.575; incremental cost-effectiveness ratio £47,768). The least costly strategy had a 46.4% probability of being cost-effective at £30,000 willingness-to-pay threshold.",

author = "G. Mowatt and R. Hern{\'a}ndez and M. Castillo and N. Lois and A. Elders and C. Fraser and O. Aremu and W. Amoaku and J. Burr and A. Lotery and C. Ramsay and A. Azuara-Blanco",

year = "2014",

month = nov,

doi = "10.3310/hta18690",

language = "English",

volume = "18",

pages = "1--253",

journal = "Health Technology Assessment",

issn = "1366-5278",

publisher = "NIHR Health Technology Assessment programme",

number = "69",

}

Mowatt, G, Hernández, R, Castillo, M, Lois, N, Elders, A, Fraser, C, Aremu, O, Amoaku, W, Burr, J, Lotery, A, Ramsay, C & Azuara-Blanco, A 2014, 'Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation', Health Technology Assessment, vol. 18, no. 69, pp. 1-253. https://doi.org/10.3310/hta18690

TY - JOUR

T1 - Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration

T2 - a systematic review and economic evaluation

AU - Mowatt, G.

AU - Hernández, R.

AU - Castillo, M.

AU - Lois, N.

AU - Elders, A.

AU - Fraser, C.

AU - Aremu, O.

AU - Amoaku, W.

AU - Burr, J.

AU - Lotery, A.

AU - Ramsay, C.

AU - Azuara-Blanco, A.

PY - 2014/11

Y1 - 2014/11

N2 - Results: In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity [95% confidence interval (CI)] was 88% (46% to 98%) and 78% (64% to 88%) respectively. For monitoring, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. The FFA for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (£39,769; QALYs 10.473) and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (£44,649; QALYs 10.575; incremental cost-effectiveness ratio £47,768). The least costly strategy had a 46.4% probability of being cost-effective at £30,000 willingness-to-pay threshold.

AB - Results: In pooled estimates of diagnostic studies (all TD-OCT), sensitivity and specificity [95% confidence interval (CI)] was 88% (46% to 98%) and 78% (64% to 88%) respectively. For monitoring, the pooled sensitivity and specificity (95% CI) was 85% (72% to 93%) and 48% (30% to 67%) respectively. The FFA for diagnosis and nurse-technician-led monitoring strategy had the lowest cost (£39,769; QALYs 10.473) and dominated all others except FFA for diagnosis and ophthalmologist-led monitoring (£44,649; QALYs 10.575; incremental cost-effectiveness ratio £47,768). The least costly strategy had a 46.4% probability of being cost-effective at £30,000 willingness-to-pay threshold.

U2 - 10.3310/hta18690

DO - 10.3310/hta18690

M3 - Article

AN - SCOPUS:84913525336

SN - 1366-5278

VL - 18

SP - 1

EP - 253

JO - Health Technology Assessment

JF - Health Technology Assessment

IS - 69

ER -

Optical coherence tomography for the diagnosis, monitoring and guiding of treatment for neovascular age-related macular degeneration: a systematic review and economic evaluation

Abstract

Access to Document

Fingerprint

Cite this